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Can You Predict What
Happens When EuroSCORE
Weds Biomarker?*
Richard A. Lange, MD
San Antonio, Texas
Accurately predicting the mortality and morbidity associ-
ated with cardiac surgery provides patients with an indica-
tion of their individual risk and permits comparison of
outcomes among different surgeons and surgical facilities.
Several scoring systems predict early outcome from cardiac
surgery. Among the most extensively validated is the European
System for Cardiac Operative Risk Evaluation (EuroSCORE)
(1). Although frequently used, it has well-recognized limi-
ations (2). After assessing the presence of variables related
o patient characteristics, procedural factors and underlying
ardiac conditions, the EuroSCORE is calculated using
ither the additive or the logistic versions. The latter is less
asy to calculate, but potentially more accurate in high-risk
atients (3,4). Conversely, both the additive and logistic
uroSCOREs may overestimate the in-hospital mortality
isk in low-risk coronary artery bypass patients (5).
See page 672
In contradistinction to surgical patients, risk stratification
in medical patients with known or suspected cardiac disease
is typically accomplished in conjunction with assessment of
biomarkers that are reflective of the severity of inflammation
(i.e., high-sensitivity C-reactive protein [hsCRP]), hemo-
dynamic stress (i.e., N-terminal pro–B-type natriuretic pep-
tide [NTproBNP]), or myocyte integrity (i.e., high-
sensitive troponin T [hsTNT]). Numerous studies have
demonstrated the utility of these biomarkers for providing
prognostic information in individuals with various cardiac
diseases, including subclinical atherosclerosis, acute coro-
nary syndromes (ACS), ST-segment elevation myocardial
infarction, valvular heart disease, cardiomyopathy, and con-
gestive heart failure (6,7).
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contents of this paper to disclose.Surprisingly, few published studies have reported on the
additive value of serum cardiac biomarker levels—measured
pre-operatively—to the EuroSCORE in predicting post-
operative mortality and morbidity. When used in combina-
tion with the EuroSCORE, serum troponin I levels ob-
tained 24 h after cardiac surgery significantly improved early
identification of high-risk patients. However, the diagnostic
value of pre-operative serum troponin I measurements was
limited and considered useless for routine cardiac surgical
practice (8). Cuthbertson et al. showed that pre-operative
serum NTproBNP levels predicted early outcome after cardiac
surgery independent of traditional indicators and conventional
risk prediction scores (9), but their prognostic utility was
modest, and their additive value to the EuroSCORE was not
assessed.
Recent interest has focused on identifying novel biomark-
ers that assess multiple pathophysiologic processes (i.e.,
inflammation, oxidative stress, myocardial strain, ischemia)
with the hope that they could predict cardiac risk across a
spectrum of cardiac disease more accurately than the tradi-
tional biomarkers that more narrowly focus on a single
pathway. One such biomarker is growth differentiation
factor (GDF)-15, which is involved in regulating inflam-
matory and apoptotic pathways needed for development,
differentiation, and tissue repair in various organs. It is one
of the more than 40 members of the transforming growth
factor  superfamily and was originally identified in acti-
ated macrophages; hence its original designation as mac-
ophage inhibitory cytokine (MIC)-1. It is expressed at low
evels in most tissues, including heart, lung, kidney, brain,
iver, and the intestine (10). However, substantial up-
egulation occurs in a wide range of cancers and in many
issues following injury, ischemia, and other forms of stress.
ith respect to the cardiovascular system, GDF-15 is
trongly expressed by activated macrophages (i.e., in athero-
clerotic plaques) and cardiomyocytes exposed to ischemia
r increased wall stress (11,12). GDF-15 protects against
ardiac injury in animal models, possibly because of its
ntiapoptotic, anti-inflammatory, or antihypertrophic ef-
ects (10–12).
GDF-15 is thought to be a marker, rather than a
ediator, of cardiovascular disease in humans (13). Plasma
evels have been independently and positively associated
ith age, male, symptomatic heart failure, reduced kidney
unction, current smoking, diabetes mellitus, waist-to-hip
atio, serum BNP, and hsCRP levels and inversely associ-
ted with high-density lipoprotein and low-density lipopro-
ein levels (14–17). These associations indicate that
DF-15 integrates several important biochemical and clin-
cal indicators of a poor prognosis in patients with, or at risk
or, cardiac disease. However, because these variables only
artly explain the variation in plasma GDF-15 levels, there
re likely additional undefined factors that have an impact
n its serum concentration.
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February 12, 2013:682–4 What Happens When EuroSCORE Weds Biomarker?Studies have shown that plasma GDF-15 levels add
incremental prognostic information to standard biomarkers
and risk factors in individuals with various cardiovascular
diseases. GDF-15 is independently associated with subclin-
ical coronary atherosclerosis and a strong predictor of all
cause and cardiovascular mortality in community-dwelling
individuals, adding incremental value to traditional risk
factors and to serum NTproBNP and hsCRP levels (14,18).
GDF-15 is a marker of mortality and recurrent MI in
individuals presenting with chest pain (19) and mortality in
patients with ST-segment elevation myocardial infarction
(20). In chronic heart failure patients, elevated plasma
concentrations of GDF-15 are a marker of increased mor-
tality and provide independent prognostic information be-
yond established clinical and biochemical markers.
In ACS patients, plasma GDF-15 levels measured at
presentation are an independent predictor of 1-year mortal-
ity (16) and levels measured after stabilization are an
independent risk marker for recurrent cardiovascular events,
including death, MI, and congestive heart failure. The
prognostic information provided by GDF-15 is incremental
to established clinical risk indicators and biomarkers (17).
Because serum GDF-15 concentration does not change
significantly from baseline to follow-up at 4 months in ACS
patients nor does it decrease in response to statin therapy, it
“appears to be a marker of pathobiological mechanisms that
is distinct from those identified by hsCRP and of ventricular
stress identified by BNP . . . and is not directly related to the
causal pathway for modification of risk by statin therapy”
(17). However, patients presenting with an ACS and high
plasma GDF-15 levels benefit more from an aggressive
interventional approach than patients with low levels of this
marker (21). Thus, GDF-15 has the potential to become a
clinically useful novel biomarker not only because it provides
independent prognostic information, but also because de-
termination of its level may also impact the therapy of
patients.
In light of the limitations of current surgical risk assess-
ment and the introduction of more versatile biomarkers,
Heringlake and colleagues investigated the usefulness of
plasma GDF-15 for risk stratification in patients undergoing
cardiac surgery in comparison with the additive EuroSCORE
and plasma NTproBNP and hsTNT levels (22). Their pro-
spective, observational cohort study showed that pre-
operative plasma GDF-15 level is an independent predictor
of post-operative mortality—both 30-day and 1-year—and
morbidity in patients referred for cardiac surgery. Further-
more, GDF-15 improved risk stratification beyond the
EuroSCORE and traditional risk markers such as NT-
proBNP and hsTNT.
The combined model of GDF-15 and additive EuroSCORE
was significantly better for predicting 30-day mortality than
the surgical score alone (area under the receiver-operating
characteristic curve: 0.85 vs. 0.81; p  0.0091). The
application of this finding to patient care may not be readily
apparent, so a more clinically meaningful interpretation isthat identification of an elevated GDF-15 resulted in a 41%
net reclassification improvement (i.e., the proportion of
individuals with events who move up or down a risk
category and the proportion of individuals with nonevents
who move up or down a risk category) compared to the
additive EuroSCORE alone (p  0.001). For comparison,
elevated NTproBNP or hsTNT did not result in significant
reclassification. GDF-15 outperformed traditional bio-
markers by providing important prognostic information
across the entire range of EuroSCORE risk categories and
in patients referred for elective cardiac surgeries as well as
those undergoing urgent of emergent procedures. Hence,
pre-operative GDF-15 plasma levels significantly improve
risk stratification of patients undergoing cardiac surgery
beyond that obtained by currently used risk scores and
biomarkers.
Although the pathophysiologic mechanisms responsible
for these findings are not precisely known, the results are
consistent with previously mentioned studies showing that
plasma GDF-15 levels provide independent and incremen-
tal prognostic information across a broad spectrum of
cardiovascular disease. Despite these promising findings,
several issues need to be addressed before measurement of
plasma GDF-15 levels is routinely recommended for pre-
operative risk stratification. First, forthcoming studies need
to define the most appropriate cutoff levels for GDF-15 to
accurately identify increased cardiovascular risk. The cut off
value of 1.8 ng/ml used in this study is similar to that
derived from ACS patients. However, different cutoff values
(i.e., 0.86 ng/ml) have been utilized for assessing prognostic
risk in community-dwelling individuals without known
heart disease (based on baseline concentrations 90th
percentile of the control population) (23) and in patients
with chronic heart failure (i.e., 2,729 ng/ml, from best
receiver-operating characteristic curve–derived cutoff level).
Second, the findings need to be confirmed in a large
population study that assesses the entire spectrum of physi-
ologic variables to determine if they influence GDF-15 levels.
Although the investigators of this study intended to analyze
the association between pre-operative GDF-15 levels and
clinical outcomes in a “derivation” cohort of patients undergo-
ing cardiac surgery and confirm the findings in a “validation”
cohort of patients, loss of plasma specimens and low event rate
forced them to use the entire cohort for validation of cut-off
levels that were derived from previous studies in ACS patients.
When the contribution of a new marker to an existing model
is performed and assessed using the same sample, the results
may be overly optimistic. Last, it remains to be determined if
the incremental information gained from GDF-15 measure-
ments will be useful in altering therapy and clinical outcomes.
If a higher predicted risk of overall mortality does not translate
directly into changes in therapy that improve outcome, then it
will be hard to justify routine pre-operative measurement of
plasma GDF-15 levels.
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